Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2-mutant mesothelioma.

Life science alliance - 1 Oct 2025

Cunningham Richard, Jia Siyang, Purohit Krishna, Fairley Michaela Noskova, Maniak Marcin K, Lin Yue, Hui Ning Sze, Graham Rebecca E, Rossi Adriano G, Cholewa-Waclaw Justyna, Bagnaninchi Pierre O, Carragher Neil O, Hansen Carsten Gram

Abstract excerpt

As the core, tumorigenic downstream effectors of the Hippo signalling pathway, YAP/TAZ and the TEAD family of transcription factors represent attractive targets for drug discovery efforts within cancer research. This is particularly true in the context of pleural mesothelioma, in which there are many recent preclinical developments and clinical trials evaluating the efficacy of TEAD inhibitors. The range of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hippo Signaling Pathway

Share to Mesothelioma

Share to Mesothelioma, Malignant

Share to Neurofibromin 2

Share to Pleural Neoplasms

Share to YAP-Signaling Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 40744733
DOI: 10.26508/lsa.202503241
PMCID: PMC12314556

Genes

NF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2-mutant mesothelioma.PMID 40744733Read ↗

Development of a pipeline to evaluate YAP-TEAD inhibitor potential <i>-</i> direct TEAD inhibition represses cancerous growth in a <i>NF2</i> -mutant model of mesotheliomaSemantic proximity Read ↗

YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.Semantic proximity Read ↗

A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma ModelsSemantic proximity Read ↗

Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient MesotheliomaSemantic proximity Read ↗

Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.Semantic proximity Read ↗

Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcriptionSemantic proximity Read ↗

Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR InhibitionSemantic proximity Read ↗

Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant linesSemantic proximity Read ↗

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancersSemantic proximity Read ↗

Integrated genomics identify novel immunotherapy targets for malignant mesotheliomaSemantic proximity Read ↗

Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEADSemantic proximity Read ↗

The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Target and Compound EvaluationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.